Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
99.03B
Market cap99.03B
Price-Earnings ratio
21.03
Price-Earnings ratio21.03
Dividend yield
0.39%
Dividend yield0.39%
Average volume
1.05M
Average volume1.05M
High today
$965.48
High today$965.48
Low today
$945.95
Low today$945.95
Open price
$953.02
Open price$953.02
Volume
933.26K
Volume933.26K
52 Week high
$991.73
52 Week high$991.73
52 Week low
$591.52
52 Week low$591.52

Stock Snapshot

Regeneron(REGN) stock is priced at $960.00, giving the company a market capitalization of 99.03B. It carries a P/E multiple of 21.03 and pays a dividend yield of 0.39%.

On 2026-11-18, Regeneron(REGN) stock moved within a range of $945.95 to $965.48. With shares now at $960.00, the stock is trading +1.5% above its intraday low and -0.6% below the session's peak.

Trading activity shows a volume of 933.26K, compared to an average daily volume of 1.05M.

The stock's 52-week range extends from a low of $591.52 to a high of $991.73.

The stock's 52-week range extends from a low of $591.52 to a high of $991.73.

REGN News

Simply Wall St 2h
Regeneron Pharmaceuticals Wins EU Libtayo Flexibility, Is The 2% Discount Enough? - Simply Wall St

...

Regeneron Pharmaceuticals Wins EU Libtayo Flexibility, Is The 2% Discount Enough? - Simply Wall St
Seeking Alpha 4h
CytomX to receive $5M from Regeneron for cancer drug milestone

CytomX Therapeutics (CTMX) announced it will receive a $5 million payment after reaching a preclinical milestone in its cancer drug development partnership with...

CytomX to receive $5M from Regeneron for cancer drug milestone
TipRanks 9h
CytomX Therapeutics triggers $5M milestone payment in Regeneron collaboration

CytomX Therapeutics (CTMX) announced the achievement of a preclinical milestone for one of the lead programs in its collaboration with Regeneron (REGN), trigger...

Analyst ratings

67%

of 30 ratings
Buy
66.7%
Hold
33.3%
Sell
0%

More REGN News

Seeking Alpha 11h
Regeneron wins EU nod for alternative Libtayo regimen

Regeneron wins EU nod for alternative Libtayo regimen Nov 17, 2026, 2:17 PM ET Regeneron Pharmaceuticals, Inc. (REGN) Stock By : Dulan Lokuwithana, SA News Edit...

Regeneron wins EU nod for alternative Libtayo regimen
TipRanks 18h
Regeneron reports EC approval for Libtayo alternative, flexible dosing schedule

Regeneron (REGN) announced that the European Commission, or EC, has approved an alternative, flexible dosing schedule for Libtayo across all approved skin, lung...

TipRanks 19h
Regeneron price target raised to $1,075 from $917 at Barclays

Barclays raised the firm’s price target on Regeneron (REGN) to $1,075 from $917 and keeps an Overweight rating on the shares. Published first on TheFly – the u...

Simply Wall St 3d
Can Regeneron Pharmaceuticals Stay Below Fair Value After Trial Wins?

has climbed strongly in recent years, and with the stock last closing at US$955.47 the obvious question is whether that price still lines up with what its earni...

Can Regeneron Pharmaceuticals Stay Below Fair Value After Trial Wins?
The Motley Fool 4d
Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?

Commercial-stage biotech companies make great investments for those of us looking for both safety and growth. Their portfolios of commercialized products offer...

Regeneron Has $16 Billion in Net Cash and Trades Near 20 Times Earnings. Is It the Cheapest Big Biotech?
Benzinga 5d
Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Phase 2 PINNACLE trial results showing its investigational antibody baloncibart reduces abnormal standing...

Regeneron Drug Lowers Standing Heart Rate And Improves Symptoms In Heart Disease Study
TipRanks 5d
Regeneron’s baloncibart reduces orthostatic heart rate in Phase 2 trial

Regeneron (REGN) announced results from the Phase 2 PINNACLE trial in adults with postural orthostatic tachycardia syndrome, or POTS, evaluating baloncibart, a...

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.